NetScientific is a transatlantic IP commercialisation company focussed on differentiated and game changing medical technologies across five core assets. Selected by a highly relevant clinical/scientific board, NSCI provides exposure to potentially disruptive companies in diagnostics, digital health delivery and therapeutics. Our analysis shows that >70% of the core portfolio value lies within Glycotest, liver testing for hepatocellular carcinoma, and Vortex, circulating tumour cell isolation. A ....
30 Oct 2018
Initiation of coverage – a strong and focused portfolio
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Initiation of coverage – a strong and focused portfolio
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
30 Oct 2018 -
Author:
John Cummins -
Pages:
34
NetScientific is a transatlantic IP commercialisation company focussed on differentiated and game changing medical technologies across five core assets. Selected by a highly relevant clinical/scientific board, NSCI provides exposure to potentially disruptive companies in diagnostics, digital health delivery and therapeutics. Our analysis shows that >70% of the core portfolio value lies within Glycotest, liver testing for hepatocellular carcinoma, and Vortex, circulating tumour cell isolation. A ....